Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks
09:09am, Wednesday, 01'st Mar 2023
Markets are trying to rise, and these companies are helping out.
Sarepta Therapeutics, Inc. (SRPT) Q4 2022 Earnings Call Transcript
09:56pm, Tuesday, 28'th Feb 2023
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
09:05pm, Tuesday, 28'th Feb 2023
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 3.12% and 3.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta stock surges more than 10% as results top expectations, drug given priority review
04:45pm, Tuesday, 28'th Feb 2023
Sarepta Therapeutics Inc. SRPT shares rallied in the extended session Tuesday after the biotech drug maker topped Wall Street expectations, and said U.S. regulators granted a priority review status fo
7 Biotech Stocks That Will Make You Rich in 10 Years
03:44pm, Wednesday, 18'th Jan 2023
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they'r
Sarepta: Raised Financial Guidance, Looming Catalyst Makes This Worth A Look
12:17pm, Tuesday, 17'th Jan 2023
Sarepta Therapeutics, Inc. net product revenues for Q4 2022 are expected to come in about 32% higher at $235.5 million; Financial results for Q4 2022 are expected late February 2023. BLA of SRP-9001 f
2 Under-the-Radar Biotech Stocks to Buy in 2023
08:45am, Friday, 06'th Jan 2023
These biotechnology stocks are pushing ahead with promising innovations.
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:30am, Tuesday, 03'rd Jan 2023
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pr
2 Top Healthcare Stocks to Buy for the Long Haul
02:53pm, Friday, 09'th Dec 2022 The Motley Fool
These two companies are just getting started.
Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?
04:31pm, Friday, 02'nd Dec 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?
12:48pm, Friday, 02'nd Dec 2022
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:00pm, Wednesday, 30'th Nov 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2022 t
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
05:07pm, Tuesday, 29'th Nov 2022 Zacks Investment Research
The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
01:32pm, Tuesday, 29'th Nov 2022
The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
09:28am, Monday, 28'th Nov 2022
The FDA said Monday it will perform a speedy review of Sarepta Therapeutics' muscular dystrophy gene therapy, and SRPT stock jumped. The post Sarepta Surges As It Nears The Finish Line With A Muscular
